<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04089059</url>
  </required_header>
  <id_info>
    <org_study_id>ETX-HFS-PA-03</org_study_id>
    <nct_id>NCT04089059</nct_id>
  </id_info>
  <brief_title>PROACTIVE-HF IDE Trial Heart Failure NYHA Class III</brief_title>
  <acronym>PROACTIVE-HF</acronym>
  <official_title>A Prospective, Multi-Center, Randomized, Controlled, Single Blind Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class III Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endotronix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endotronix, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, controlled, single blind, multicenter clinical trial to
      evaluate the safety and effectiveness of the Cordella PA Sensor System in NYHA Class III
      Heart Failure Patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality and HF Hospitalizations or Emergency Department/ Hospital Outpatient IV diuretic visits.</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of mortality and HF Hospitalizations or Emergency Department/ Hospital Outpatient IV diuretic visits. The rate in each arm is calculated as the total number of observed events in each arm divided by the total observed exposure time in each arm from randomization through 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Device/system related complication</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from device/system related complication at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Pressure sensor failure</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from pressure sensor failure at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HF Hospitalizations</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Number of HF Hospitalizations at 6 and 12 months post-implant compared to the number of HF Hospitalizations in the 6 and 12 months prior to implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HF Hospitalizations, Emergency Department/ Hospital Outpatient IV diuretic visits and all-cause mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Combined outcome of
First and recurrent HF Hospitalizations
Emergency Department/ Hospital Outpatient IV diuretic visits
all-cause mortality
at 6 months, added together with equal weighting into a total number of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure hospitalization or Emergency Department / Hospital Outpatient IV diuretic visits</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Heart failure hospitalization or Emergency Department / Hospital Outpatient IV diuretic visits at 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac and all-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IV diuretic visits</measure>
    <time_frame>3 years</time_frame>
    <description>Intravenous (IV) diuretic visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication changes</measure>
    <time_frame>3 years</time_frame>
    <description>Heart failure related Medication changes will be collected and summarized by visit presenting the percentage of subjects with and without any change in Heart Failure related medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Artery Pressure (PAP) I</measure>
    <time_frame>3 years</time_frame>
    <description>Change in Pulmonary Artery Pressure (PAP) from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Artery Pressure (PAP) II</measure>
    <time_frame>3 years</time_frame>
    <description>Change in Pulmonary Artery Pressure (PAP) before and after 6-Minute Walk Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Artery Pressure (PAP) III</measure>
    <time_frame>3 years</time_frame>
    <description>Change in Pulmonary Artery Pressure (PAP) for patients blinded (12 month) vs patients unblinded (12 month) to PAP measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>3 years</time_frame>
    <description>Percentage of device success as documented by ability of the System to successfully transmit PAP data to a secure database</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KCCQ</measure>
    <time_frame>3 years</time_frame>
    <description>The Quality of Life KCCQ questionnaire is a measure of health-related quality of life. It is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life related to Heart Failure. Out of 23-items, 10 scores will be calculated: Physical Limitation, Symptom Stability, Symptom Frequency, Symptom Burden, Total Symptom Score, Self-Efficacy, Quality of Life, Social Limitation, Overall Summary Score, Clinical Summary Score .Presentation will be done by means of descriptive statistics including the absolute value and change from baseline by visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA</measure>
    <time_frame>3 years</time_frame>
    <description>Subjects complete a six (6) minute walk test at the study visits described in the study protocol. Total distance walked (meters) will be collected and analyzed by means of descriptive statistics including the absolute value and change from baseline by visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA and 6-Minute Walk Test</measure>
    <time_frame>3 years</time_frame>
    <description>The NYHA functional classification categorizes the extent of heart failure by placing subjects in one of four (I, II, III, IV) categories based on how much they are limited during physical activity and symptoms of shortness of breath and/or angina. Shifts in NYHA functional classification from baseline over all post-baseline visits will be presented . Subjects complete a six (6) minute walk test at the study visits described in the study protocol. Total distance walked (meters) will be collected and analyzed by means of descriptive statistics including the absolute value and change from baseline by visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure sensor failure</measure>
    <time_frame>3 years</time_frame>
    <description>Pressure sensor failure rate throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Frequency of serious adverse events throughout the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">970</enrollment>
  <condition>Heart Failure NYHA Class III</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pulmonary Artery Pressure Guided Heart Failure Management (PAPGHFM) and Guideline Directed Medical Therapy (GDMT) considering daily Pulmonary Artery Pressure (PAP) measurements and vital signs collected by Cordella Heart Failure System (CHFS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Proactive subject management according to GDMT leveraging also the vital signs collected by CHFS.
After month 12 all data (including PAP measurements) will be available for both the subject and the clinician and the clinician will then treat the subject's HF per PAPGHFM and GDMT considering daily PAP measurements and the vital signs collected by CHFS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cordella™ Pulmonary Artery Sensor System</intervention_name>
    <description>The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management and comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.
Cordella Sensor
Cordella Delivery System
myCordella Patient Reader
Reader Dock
Cordella Calibration Equipment (CalEQ)
myCordella Hub
Cordella Data Analysis Platform (CDAP)</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cordella™ Pulmonary Artery Sensor System</intervention_name>
    <description>The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management and comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.
Cordella Sensor
Cordella Delivery System
myCordella Patient Reader
Reader Dock
Cordella Calibration Equipment (CalEQ)
myCordella Hub
Cordella Data Analysis Platform (CDAP)</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has given written informed consent

          2. Male or female, at least 18 years of age

          3. Diagnosis and treatment of HF (regardless of left ventricular ejection fraction
             (LVEF)) for ≥ 3 months and NYHA Class III HF at time of Screening

          4. Subjects should be on stable, optimally titrated medical therapy for at least 30 days,
             as recommended according to current American Heart Association (AHA)/American College
             of Cardiology (ACC) guidelines as standard-of-care for HF therapy in the United
             States, with any intolerance documented.

          5. HF related hospitalization, HF treatment in a hospital day-care setting, or urgent
             outpatient clinic HF visit for IV diuretics within 12 month (last hospitalization
             should be 30 days before Screening /Enrollment) and/or N-terminal pro B-type
             Natriuretic Peptide (NT-proBNP) at time of Screening/ Enrollment defined as:

               1. Subjects with LVEF ≤ 50%: NT-proBNP ≥ 1500 pg/mL.

               2. Subjects with LVEF &gt; 50%: NT-proBNP ≥ 800 pg/mL .

             Thresholds for NT-proBNP (for both LVEF ≤ 50% and LVEF &gt; 50%) will be corrected for
             body mass index (BMI) using a 4% reduction per BMI unit over 25 kg/m2

          6. Subjects should be on diuretic therapy

          7. Subjects who are physically able to hold the myCordella™ Patient Reader unit
             (approximate weight 1.3lb) against the ventral thoracic surface for up to 2 minutes
             per day while in a seated position, as well as dock and undock the myCordella™ Patient
             Reader

          8. Subjects with sufficient eyesight, hearing, and mental capacity to respond to the
             myCordella™ Patient Reader's audio/visual cues and operate the myCordella™ Patient
             Reader

          9. Subject has sufficient Cellular and/ or Wi- Fi Internet coverage at home

         10. Subject agrees to return to the treating Investigator for all scheduled follow up
             visits and can return to the hospital for follow up

        Exclusion Criteria:

          1. Intolerance to all neuro-hormonal antagonists (i.e., intolerance to angiotensin
             converting enzyme-inhibitors (ACE-I), angiotensin receptor blockers (ARB),
             angiotensin-neprilysin inhibitors (ARNI), and beta-blockers) due to hypotension or
             renal dysfunction

          2. ACC/AHA Stage D refractory HF (including having received or currently receiving
             pharmacologic circulatory support with inotropes)

          3. Subjects with history of recurrent (&gt; 2) pulmonary embolism or deep vein thrombosis

          4. Subjects who have had a major cardiovascular (CV) event (e.g., myocardial infarction,
             stroke) within 3 months of the Screening Visit

          5. Unrepaired severe valvular disease

          6. Subjects with congenital heart disease or mechanical/tissue right heart valve(s)

          7. Subjects with known coagulation disorders

          8. Subjects with a hypersensitivity or allergy to platelet aggregation inhibitors
             including aspirin, clopidogrel, prasugrel, and ticagrelor; or patients unable to take
             dual antiplatelet or anticoagulants for one- month post implant

          9. Known history of life threatening allergy to contrast dye

         10. Subjects whereby RHC is contraindicated

         11. Subjects with an active infection at the Cordella PA Sensor Implant Visit

         12. Subjects with a Glomerular Filtration Rate (GFR) &lt;25 ml/min or who are on chronic
             renal dialysis

         13. Implanted with Cardiac Resynchronization Therapy (CRT)-Pacemaker (CRT-P) or
             CRT-Defibrillator (CRT-D) for less than 90 days prior to screening visit

         14. Received or are likely to receive an advanced therapy (e.g., mechanical circulatory
             support or lung or heart transplant) in the next 12 months

         15. Subjects who are pregnant or breastfeeding

         16. Subjects who are unwilling or deemed by the Investigator to be unwilling to comply
             with the study protocol, or subjects with a history of non-compliance

         17. Severe illness, other than heart disease, which would limit survival to &lt;1 year

         18. Subjects whose clinical condition, in the opinion of the Investigator, makes them an
             unsuitable candidate for the study

         19. Subjects enrolled in another investigational trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Sauerland</last_name>
    <role>Study Director</role>
    <affiliation>Endotronix, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Delano</last_name>
    <phone>+1 630 473 3200</phone>
    <phone_ext>209</phone_ext>
    <email>christine.delano@endotronix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Heart, PLLC</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Sellberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCFS Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandar Aras, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Teuteberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Gluck, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Health</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russell Stapleton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>USF Health</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Fernandez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loyola University</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Heroux, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heart Centers of Illinois</name>
      <address>
        <city>Palos Park</city>
        <state>Illinois</state>
        <zip>60464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Macaluso, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OSF Healthcare</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Sparrow, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kiernan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Cowger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kariann Abbate, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vlad Cotarlan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monique Tanna, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gavin Hickey, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Donald Guthrie Foundation</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudhakar Sattur, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PRISMA Health- Upstate</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Guichard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Heart</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faisel Syed, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Craig Cardiovascular Center</name>
      <address>
        <city>Gonzales</city>
        <state>Texas</state>
        <zip>78155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Craig, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>INOVA Health</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Cole, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Health Care</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Mudd, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Froedtert Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Saltzberg, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Heart Disease</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Pulmonary Artery Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

